Overview
Updated 14 Jul 2026
Sara Tolaney, MD, is Chief, Division of Breast Oncology, Dana-Farber Cancer Institute. The public record shows 1,337 publications with 37,487 citations (h-index 85), centered on Advanced Breast Cancer Therapies, HER2/EGFR in Cancer Research, Cancer Treatment and Pharmacology. It also documents an investigator role on 22 registered clinical trials, industry payments reported by 40 companies, 1 NIH-funded awards (2024–2026).
- Most recent indexed publication: 2026 · JNCI cancer spectrum
- Top research focus: Advanced Breast Cancer Therapies
- 22 registered trials on ClinicalTrials.gov
- Open Payments reporting from 40 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 109 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 359.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 22 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
InvestigatorPhase 3RecruitingNCT06492616 - Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
InvestigatorPhase 3RecruitingNCT05812807 - ATEMPT 2.0: Adjuvant T-DM1 vs TH
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 2RecruitingNCT04893109
Industry payments
Updated 14 Jul 2026
40 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- F. Hoffmann-La Roche AGProgram year202511 payments$29,218openpaymentsdata.cms.gov ↗
- Gilead Sciences, Inc.Program year202515 payments$24,349openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202511 payments$21,703openpaymentsdata.cms.gov ↗
NIH funding
Updated 14 Jul 2026
1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies.
JNCI cancer spectrum
2026
Most-cited worksby citation count (OpenAlex)
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Residency
Internal Medicine, Johns Hopkins University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Fellowship
Hematology and Medical Oncology, Dana-Farber Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Board Certified: Internal Medicine
Hematology, Medical Oncology (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Editorial & leadership rolesjournal and society appointments
- Member
National Cancer Institute Breast Cancer Steering Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Vice Chair for Late-Stage Development in Breast Cancer
Alliance for Clinical Trials in Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - Chair
multiple phase 3 breast cancer clinical trials (e.g., DESTINY-Breast09, ASCENT-04, ASCENT-03, TROPICS-02, ATEMPT)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Awards & honorshonors on the public record
- Top Doctor Award2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliationsappointments beyond the home institution
- Brigham and Women's Hospital
Department of Medical Oncology, Boston, MA
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →physiciandirectory.brighamandwomens.org ↗ - Co-Leader
Breast Cancer Research Program, Dana-Farber/Harvard Cancer Center; Member, Center Scientific Council
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dfhcc.harvard.edu ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Podcast guest discussing tucatinib/TDXd for CNS metastases in HER2+ breast cancer
Breast Cancers Today podcast
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/sara-tolaney-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Sara-Tolaney
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/stolaney1
Mentions by otherswhere others cite or feature them
- Instagram
instagram.com/danafarber_breast
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Other
mantacares.com/blogs/podcast-landing/patient-from-hell-podcast-ep-82-rewriting-the-story-of-triple-negative-breast-cancer-with-dr-sara-tolaney
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mantacares.com ↗ - Other
vjoncology.com/speaker/sara-tolaney
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjoncology.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Richardson, MD
Harvard University
- 2,062
- publications
- 172
- h-index
- 17
- trials
Pasi Janne, MD, PhD
Harvard University
- 2,385
- publications
- 163
- h-index
- 15
- trials
Steven Greenberg, MD
Harvard University
- 954
- publications
- 144
- h-index
- 9
- trials
David Scadden, MD
Harvard University
- 665
- publications
- 124
- h-index
- 4
- trials